Abbreviations

AP: Acute Pneumonia; COVID-19: Coronavirus Disease; SARS: Severe Acute Respiratory Syndrome; MERS: Middle East Respiratory Syndrome

The problem of AP belongs to the category of those scientific topics that have not been subjected to a serious conceptual revision. Discussions on this topic in recent decades have had a pre-known direction, where the pathogen was assigned the place of the main cause of the disease, and the essence of the dispute was to find the most effective way to neutralize it. The beginning of the COVID-19 pandemic, which gave a stream of patients with monoetiological inflammation and an infinite number of clinical options, did not affect the ideology of the problem and the search for a "pill for pneumonia". "Cognitive bias" with adherence to certain stereotypes and the difficulty of changing attitudes, despite contradictions and facts, are the main obstacles to future promising solutions [1].

References

1. I Zagury-Orly and RM Schwartzstein. “Covid-19 A Reminder to Reason”. The New England Journal of Medicine 383 (2020): e12.
2. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 86 (2008): 408-416.
3. WHO Revised global burden of disease 2002 estimates (2004).
4. https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome
5. Ruuskanen O., et al. “Viral pneumonia". Lancet9973 (2011): 1264-1275.
6. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine 2 (2019): 139-152.
7. JP Metlay., et al. “On behalf of the American Thoracic Society and Infectious Diseases Society of America. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
8. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases (2020): ciaa530.
9. Beović M., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy (2020): 326.
10. Kim D., et al. “Rates of co-infection between SARS-CoV-2 and other respiratory pathogens”. The Journal of the American Medical Association 323 (2020): 2085-2086.
11. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
12. Alhazzani W., et al. “Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)”. Critical Care Medicine (2020).
13. Keeley AJ., et al. “Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?” Thorax 75 (2020): 621-622.
14. Ing AJ., et al. “COVID-19: in the footsteps of Ernest Shackleton”. Thorax 75 (2020): 693-694.
15. JH Stone., et al. “Efficacy of Tocilizumab in Patients Hospitalized with Covid-19”. The New England Journal of Medicine (2020).
16. M Ackermann., et al. “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 (2020).
17. Martines RB., et al. “COVID-19 Pathology Working Group (2020). Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States”. Emerging Infectious Diseases 9 (2020): 2005-2015.
18. Igor Klepikov. "Acute pneumonia. New doctrine and first treatment results." LAP-Lambert Academic Publishing (2020).
19. Xu Chen. “Avoiding Defensive Medicine among Pandemic”. EC Emergency Medicine and Critical Care 12 (2020): 49-53.
20. VA Simonovich., et al. “A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia (2020).
21. O Mitjà., et al. “A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 (2020).
22. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results (2020).
23. E Huang and SC Jordan. “Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies”. The New England Journal of Medicine 383 (2020): 2387-2388.
24. DA Berlin., et al. “Severe Covid-19”. The New England Journal of Medicine 383 (2020): 2451-2460.
25. Rwik Sen. “High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics”. Future Drug Discovery (2020).
26. Koeckerling D., et al. “Awake prone positioning in COVID-19”. Thorax Published Online First: 16 (2020).
27. Thompson AE., et al. “Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure”. JAMA Internal Medicine (2020).
28. Winearls S., et al. “Early conscious prone positioning in patients with COVID-19 receiving continuous positive airway pressure: a retrospective analysis”. BMJ, Open Respiratory Research 7 (2020): e000711.
29. Vianello A., et al. “High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection”. Thorax (2020).
30. DA Berlin and RM Gulick FJ. “Severe Covid-19”. The New England Journal of Medicine (2020).
31. ML Ranney., et al. “Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic”. The New England Journal of Medicine 382 (2020): e41.
32. Lai J., et al. “Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019”. JAMA Network Open 3 (2020): e203976-e203976.
33. RE Leiter. “Reentry”. The New England Journal of Medicine (2020).
34. JN Rosenquist. “The Stress of Bayesian Medicine - Uncomfortable Uncertainty in the Face of Covid-19”. The New England Journal of Medicine 384 (2021): 7-9.
35. PY Boëlle., et al. “Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France”. Journal of Clinical Medicine 9 (2020): 3148.
36. C Salama., et al. “Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia”. The New England Journal of Medicine 384 (2021): 20-30.
37. Karagiannidis C., et al. “Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study”. The Lancet Respiratory Medicine 8 (2020): 853-862.
38. Renato Seligman and Beatriz Graeff Santos Seligman. “Pandemic in the 21st Century. The Challenge of COVID-19”. EC Pulmonology and Respiratory Medicine8 (2020): 30-31.
39. Grasselli G., et al. “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy”. The Journal of the American Medical Association (2020).
40. S Richardson., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”. The Journal of the American Medical Association (2020).
41. Gupta S., et al. “Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19”. JAMA Internal Medicine 11 (2020): 1436-1446.
42. A Liapikou., et al. “The management of severe community acquired pneumonia in the ICU. June 2014”. Expert Review of Respiratory Medicine 3 (2014): 293-303.
43. JW Kim., et al. “The Prognostic Factors of Pneumonia with Septic Shock in Patients Presenting to the Emergency Department”. Korean Journal of Critical Care Medicine 4 (2015): 258-264.
44. P Jason., et al. “Severe community-acquired pneumonia: timely management measures in the first 24 hours”. Critical Care 20 (2016): 237.
45. A Vidal and L Santos. “Comorbidities impact on the prognosis of severe acute community-acquired pneumonia”. Porto Biomedical Journal6 (2017): 247-346.
46. A Ceccato and A Torres. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.